AMICUS THERAPEUTICS INC (FOLD) Stock Price, Forecast & Analysis
USA - NASDAQ:FOLD - US03152W1099 - Common Stock
FOLD Key Statistics, Chart & Performance
The current stock price of FOLD is 8.99 USD. In the past month the price increased by 10.17%. In the past year, price decreased by -18.2%.
FOLD Latest News, Press Relases and Analysis
FOLD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.85 | 381.38B | ||
| AMGN | AMGEN INC | 13.6 | 159.73B | ||
| GILD | GILEAD SCIENCES INC | 15.02 | 152.62B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.29 | 108.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.95 | 66.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 830.33 | 55.51B | ||
| ARGX | ARGENX SE - ADR | 62 | 51.19B | ||
| INSM | INSMED INC | N/A | 38.63B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.99 | 33.96B | ||
| NTRA | NATERA INC | N/A | 26.96B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.20B | ||
| BIIB | BIOGEN INC | 8.92 | 21.89B |
Related stock screener links
About FOLD
Company Profile
Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. The company is headquartered in Princeton, New Jersey and currently employs 499 full-time employees. The company went IPO on 2007-05-31. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
Company Info
AMICUS THERAPEUTICS INC
47 Hulfish Street
Princeton NEW JERSEY 19104 US
CEO: John F. Crowley
Employees: 499
Phone: 16096622000
AMICUS THERAPEUTICS INC / FOLD FAQ
What does FOLD do?
Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. The company is headquartered in Princeton, New Jersey and currently employs 499 full-time employees. The company went IPO on 2007-05-31. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
What is the stock price of AMICUS THERAPEUTICS INC today?
The current stock price of FOLD is 8.99 USD. The price increased by 1.47% in the last trading session.
Does FOLD stock pay dividends?
FOLD does not pay a dividend.
What is the ChartMill rating of AMICUS THERAPEUTICS INC stock?
FOLD has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What do analysts say about AMICUS THERAPEUTICS INC (FOLD) stock?
18 analysts have analysed FOLD and the average price target is 16.32 USD. This implies a price increase of 81.54% is expected in the next year compared to the current price of 8.99.
What is the Price/Earnings (PE) ratio of AMICUS THERAPEUTICS INC (FOLD)?
AMICUS THERAPEUTICS INC (FOLD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.11).
Can you provide the market cap for AMICUS THERAPEUTICS INC?
AMICUS THERAPEUTICS INC (FOLD) has a market capitalization of 2.77B USD. This makes FOLD a Mid Cap stock.
FOLD Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to FOLD. When comparing the yearly performance of all stocks, FOLD turns out to be only a medium performer in the overall market: it outperformed 67.63% of all stocks.
FOLD Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to FOLD. FOLD has a medium profitability rating, but doesn't score so well on its financial health evaluation.
FOLD Financial Highlights
Over the last trailing twelve months FOLD reported a non-GAAP Earnings per Share(EPS) of -0.11. The EPS increased by 71.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.67% | ||
| ROE | -18.65% | ||
| Debt/Equity | 1.92 |
FOLD Forecast & Estimates
18 analysts have analysed FOLD and the average price target is 16.32 USD. This implies a price increase of 81.54% is expected in the next year compared to the current price of 8.99.
For the next year, analysts expect an EPS growth of 70.86% and a revenue growth 19.05% for FOLD